Ravulizumab

ATC L04AJ02 · 9 markets · 22 records

Ravulizumab 9 markets · 22 records Forms

AU 5 records · 4 strengths

  • 1,100 mg/11 mLinjectionUltomiris also in GB·ES
  • 300 mg/3 mLinjectionUltomiris also in GB·ES
  • 100 mg/mLinjectionULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial also in SG unknown

Records without a stated strength · 1 Ultomiris 100mg/ml

US 3 records · 3 strengths

GB 3 records · 3 strengths

CA 2 records · 1 strengths

ES 2 records · 2 strengths

TW 2 records · 1 strengths

HK 2 records · 1 strengths

    Records without a stated strength · 1 ULTOMIRIS CONCENTRATE FOR SOLUTION FOR INFUSION 1100MG/11ML

    SG 1 records · 1 strengths

    EU 1 records · 1 strengths

    EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

      Records without a stated strength · 1 Ultomiris

      Side-by-side table

      The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

      Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.